Karimkhani C, Green AC, Nijsten T, Weinstock MA, Dellavalle RP, Naghavi M, Fitzmaurice C. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duarte AF, Sousa-Pinto B, Azevedo LF, Barros AM, Puig S, Malvehy J, et al. Clinical ABCDE rule for early melanoma detection. Eur J Dermatol. 2021;31(6):771–8.

Article  PubMed  Google Scholar 

Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA: a Cancer J Clin. 1985;35(3):130–51.

CAS  Google Scholar 

Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292(22):2771–6.

Article  CAS  PubMed  Google Scholar 

Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. ImmunoTargets Ther. 2018;7(null):35–49. https://doi.org/10.2147/ITT.S134842.

Heo JR, Kim NH, Cho J, Choi KC. Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma. Oncol Rep. 2016;36(4):1779–86.

Article  CAS  PubMed  Google Scholar 

Tyrell R, Antia C, Stanley S, Deutsch GB. Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. Melanoma management. 2017;4(1):61–8.

Article  PubMed  PubMed Central  Google Scholar 

Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38(33):3947–70.

Article  CAS  PubMed  Google Scholar 

Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(4):367–402.

Article  CAS  Google Scholar 

Keilholz U, Ascierto P, Dummer R, Robert C, Lorigan P, Van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435–48.

Article  CAS  PubMed  Google Scholar 

Li J, Wang Y, Liang R, An X, Wang K, Shen G, et al. Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomed: Nanotechnol, Biol Med. 2015;11(3):769–94.

Article  CAS  Google Scholar 

Midorikawa Y, Tsuji S, Takayama T, Aburatani H. Genomic approach towards personalized anticancer drug therapy. Pharmacogenomics. 2012;13(2):191–9.

Article  CAS  PubMed  Google Scholar 

Maleki LA, Baradaran B, Majidi J, Mohammadian M, Shahneh FZ. Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Hum Antibodies. 2013;22(1–2):9–13.

Article  CAS  PubMed  Google Scholar 

Newcomer K, Robbins KJ, Perone J, Hinojosa FL, Chen D, Jones S, et al. Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. Curr Probl Surg. 2022;59(1): 101030.

Article  PubMed  Google Scholar 

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.

Raigani S, Cohen S, Boland GM. The role of surgery for melanoma in an era of effective systemic therapy. Curr Oncol Rep. 2017;19:1–5.

Article  Google Scholar 

Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19:2547–55.

Article  PubMed  PubMed Central  Google Scholar 

Lwin TM, Kaelberer Z, Ruan M, Molina G, Boland G. Surgical utilization and outcomes for patients with stage IV melanoma in the modern immunotherapy era. Ann Surg Oncol. 2023;30(8):5005–12.

Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, et al. NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines. J Nat Compr Cancer Netw. 2021;19(4):364–76.

Article  Google Scholar 

Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer J (Sudbury, Mass). 2012;18(2):176.

Article  CAS  Google Scholar 

Hsueh EC, Gupta RK, Yee R, Leopoldo ZC, Qi K, Morton DL. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol. 2000;7:232–8.

Article  CAS  PubMed  Google Scholar 

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline–Update 2016. Eur J Cancer. 2016;63:201–17.

Article  PubMed  Google Scholar 

Morris KT, Marquez CM, Holland JM, Vetto JT. Prevention of local recurrence after surgical debulking of nodal and subcutaneous melanoma deposits by hypofractionated radiation. Ann Surg Oncol. 2000;7:680–4.

Article  CAS  PubMed  Google Scholar 

Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non–small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–72.

Article  PubMed  PubMed Central  Google Scholar 

Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Rad Oncol* Biol* Physics. 2004;58(3):862–70.

Article  Google Scholar 

Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3(5): e28780.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, He J, He J, He Y, Zhang D, Kong R, Dan K. The abscopal effect of anti-CD95 and radiotherapy in melanoma. Discover Oncology. 2023;14(1):1–11.

Article  Google Scholar 

Zager JS, Sondak VK, Kudchadkar R. Melanoma. 1st ed. Oxford University Press; 2016.

Berthenet K, Ferrer CC, Fanfone D, Popgeorgiev N, Neves D, Bertolino P, et al. Failed apoptosis enhances melanoma cancer cell aggressiveness. Cell Reports. 2020;31(10):107731.

Article  CAS  PubMed  Google Scholar 

Serrone L, Zeuli M, Sega F, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res: CR. 2000;19(1):21–34.

CAS  PubMed  Google Scholar 

Huttunen KM, Mahonen N, Raunio H, Rautio J. Cytochrome P450-activated prodrugs: targeted drug delivery. Curr Med Chem. 2008;15(23):2346–65.

Article  CAS  PubMed  Google Scholar 

Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007;12(9):1114–23.

Article  CAS  PubMed  Google Scholar 

Tas F, Erturk K. Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. J Oncol Pharm Pract. 2021;27(1):40–5.

Article  CAS  PubMed  Google Scholar 

Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res. 2007;56(4):275–87.

Article  CAS  PubMed  Google Scholar 

Middleton MR, Grob J, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158.

Article  CAS  PubMed  Google Scholar 

Fuertes M, Castilla J, Alonso C, Prez J. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003;10(3):257–66.

Article  CAS  PubMed